FMC-376 is under clinical development by Frontier Medicines and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FMC-376’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FMC-376 overview

FMC-376 is under development for the treatment of KRASG12C mutant metastatic solid tumors including non-small cell lung, metastatic pancreatic and metatstatic colorectal cancers. The drug candidates act by targeting activated KRAS G12C. It is developed based on chemoproteomics platform. It is administered through oral route.

Frontier Medicines overview

Frontier Medicines, is a biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. The company is headquartered in Boston, Massachusetts, the US.

For a complete picture of FMC-376’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.